Application of staphylococcus aureus toxin protein related gene SA1833 / SA1832 in treatment of staphylococcus aureus infection
By targeting the combined use of Staphylococcus aureus toxin protein-related gene SA1833/SA1832 and antibiotics, the bacterial retention mechanism is regulated, and the chronic infection caused by methicillin-resistant Staphylococcus aureus has been solved, which has significantly reduced the survival rate and retention of bacteria. , providing effective treatment options for drug-resistant Staphylococcus aureus.
Patent Information
- Application Number
- CN202411043389.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-31
AI Technical Summary
The prior art is difficult to effectively treat drug resistance, persistence and recurrent infection caused by Staphylococcus aureus, especially chronic infection caused by methicillin Staphylococcus aureus, and lacks highly targeted drugs and strategies.
Knockout by targeting the Staphylococcus aureus toxin protein-related gene SA1833/SA1832, combined with antibiotics, reduce bacterial retention and survival rates, and use RNA-seq and RT-qPCR to identify the expression of downstream target gene lrgA and regulate the Bacterial retention mechanism.
It significantly reduces the survival and retention of Staphylococcus aureus under antibiotic treatment, and provides a new treatment regimen for methicillin-resistant Staphylococcus aureus, reducing the risk of repeated infections.
Smart Images

Figure CN119055779A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of genetic engineering, and relates to the application of Staphylococcus aureus toxin protein related genes SA1833 / SA1832 in treating Staphylococcus aureus infection. Background Art
[0002] Staphylococcus aureus is a multifunctional opportunistic pathogen that can cause a variety of infectious diseases, such as mild skin infections, toxic shock syndrome, food poisoning and chronic pneumonia, posing a major threat to global public health. Antibiotics are a common means of clinical treatment of S. aureus infections and are widely used. However, over time, S. aureus has evolved four different mechanisms: resistance, heteroresistance, tolerance and persistence to maintain the survival of bacteria in an environment containing antibiotics. Among them, the formation of resistant S. aureus is an important cause of acute S. aureus infection. Currently, by analyzing the resistance mechanism of S. aureus, a variety of antibacterial or bactericidal drugs targeting different resistance mechanisms have been developed. The combination of multiple drugs can effectively treat the acute infection caused by it. The formation of tolerant and persistent bacteria is an important cause of repeated and chronic infections caused by S. aureus in clinical practice. However, due to the small number of tolerant and persistent bacteria and the difficulty of separating them from the cell population, our understanding of the tolerance and persistence mechanism of bacteria is still relatively one-sided. There are relatively few specific drugs on the market that can target and kill persistent Staphylococcus aureus, and there is currently no better response strategy for the stubborn and recurrent infections caused by Staphylococcus aureus.
[0003] Staphylococcus aureus is a facultative anaerobic opportunistic pathogen that can colonize various parts of the human body. Under normal circumstances, Staphylococcus aureus does not cause host infection, but when the human immune system is reduced, it can invade the host through damaged skin, mucous membranes, etc., thereby causing infectious diseases of varying degrees. Infections caused by Staphylococcus aureus can be divided into infections caused by methicillin-sensitive Staphylococcus aureus and infections caused by methicillin-resistant Staphylococcus aureus according to the type of Staphylococcus aureus infected; and according to the severity of the infection, they can be divided into acute infections and chronic recurrent infections. Among them, chronic infections caused by methicillin-resistant Staphylococcus aureus have brought great challenges to the clinical treatment of Staphylococcus aureus infections, and the formation of persistent Staphylococcus aureus is an important cause of chronic recurrent infections. Therefore, it is particularly important to explore the molecular mechanism of the persistence of Staphylococcus aureus and develop drugs that kill persistent Staphylococcus aureus based on this target.
[0004] Previous studies have shown that the metabolic level, cell wall defects and virulence factors of S. aureus can affect the retention level of bacteria, and S. aureus can affect the retention of bacteria by regulating the intracellular ATP level or the expression of PSM in response to oxidative stress or stringent stress, respectively. In addition, the toxin-antitoxin system (TA) also plays an important role in the formation of bacterial retention, and the expression of toxin proteins can promote the formation of retention. The inventors found through preliminary studies that SA1833 and SA1832 are a type of gene pair widely present in methicillin-resistant S. aureus, and the gene sequence is highly conserved; it may be a type II TA-like element, in which SA1833 encodes antitoxin protein and SA1832 encodes toxin protein, and protein structure prediction shows that SA1833 and SA1833 both have DNA binding domains, and SA1833 also has a transcriptional regulatory domain. In addition, the study also found that SA1833 / SA1832 can respond to different external stresses, thereby upregulating the transcription level of SA1833 / SA1832. However, it is still unclear whether the increase in its expression level is conducive to the bacterial adaptation to the external stress environment. Overexpression of toxin proteins can promote bacterial antibiotic retention, and the complex intracellular environment of host cells, including oxidative environment, nutritional deficiency, acidic environment, etc., can induce the expression of SA1833, SA1832 and SA1833-SA1832. Whether the host intracellular pressure can promote the formation of S. aureus retention by inducing the expression of SA1833 / SA1832, thereby increasing the survival of MRSA during intracellular antibiotic treatment and promoting chronic and recurrent infections, needs further study. Summary of the invention
[0005] Based on the above research background, in this study, we identified the toxin protein SA1833 / SA1832 through RNA-seq and RT-qPCR methods and found that it can regulate the expression of downstream metabolic target gene lrgA. In order to determine the correlation between SA1833 / SA1832 and the intracellular retention of methicillin-resistant Staphylococcus aureus in host cells and its molecular mechanism for regulating the formation of S. aureus retention, we first knocked out SA1833 / SA1832 by homologous recombination, and detected the changes in the retention ability of the mutant strain under the treatment of ceftizoxime, a β-lactam antibiotic that can penetrate into the host cell. At the same time, RNA-seq and RT-qPCR methods were used to identify the downstream target genes regulated by it, hoping to provide new treatment options and strategies for persistent infections caused by MRSA strains of S. aureus.
[0006] Therefore, the present invention discloses an application of using the Staphylococcus aureus toxin protein-related gene SA1833 / SA1832 as a target to treat Staphylococcus aureus infection. Specifically, the present invention relates to the following aspects:
[0007] On the one hand, the present invention relates to the use of Staphylococcus aureus toxin protein related genes SA1833 and / or SA1832 as targets in the preparation of drugs for treating drug-resistant Staphylococcus aureus infections, preferably, the drug resistance is preferably methicillin resistance.
[0008] On the other hand, the present invention also relates to the use of gene knockout vectors or primers of Staphylococcus aureus toxin protein-related genes SA1833 and / or SA1832 in the preparation of drugs for treating drug-resistant Staphylococcus aureus infections; preferably, the primer sequence is shown in any one of SEQ ID NO.1-12; preferably, the drug resistance is preferably methicillin resistance.
[0009] Among them, the above-mentioned drug-resistant Staphylococcus aureus infections include acute infections, chronic infections and recurrent infections.
[0010] On the other hand, the present invention also relates to a pharmaceutical composition, which is preferably used to treat drug-resistant Staphylococcus aureus infection, characterized in that the pharmaceutical composition comprises a knockout vector or primer for the gene of the Staphylococcus aureus toxin protein-related gene SA1833 and / or SA1832, and an antibiotic. Preferably, the primer sequence is shown in any one of SEQ ID NO.1-12.
[0011] Wherein, the above-mentioned antibiotic is a β-lactam antibiotic, preferably cefuroxime.
[0012] On the other hand, the present invention also relates to a method for reducing the intracellular persistence of drug-resistant Staphylococcus aureus or reducing the survival rate of drug-resistant Staphylococcus aureus, characterized in that the Staphylococcus aureus toxin protein-related genes SA1833 and / or SA1832 are knocked out. In a specific embodiment of the present invention, the cells include mouse macrophages RAW264.7, but those skilled in the art can expect that it can also be used to reduce the persistence of Staphylococcus aureus in any infected cell.
[0013] Among them, the expression of the metabolism-related gene lrgA was downregulated by knocking out SA1833 and / or SA1832.
[0014] The method also includes designing specific gene knockout primers, wherein the specific gene knockout primers are shown as SEQ ID NO.1-12.
[0015] Wherein, the above primers are used to amplify the upstream and downstream homology arms of the target gene.
[0016] On the other hand, the present invention also relates to a gene knockout vector for knocking out SA1833 and / or SA1832, characterized in that it is a pBTs recombinant vector comprising a sequence shown in any one of SEQ ID NOs.33-36.
[0017] The term "persister" is defined as a dormant variant that can transiently change the physiological state of bacteria under external stress, promoting the survival of bacteria in the presence of antibiotics by reducing metabolic activity or causing the bacteria to enter a metabolically active but non-growing state.
[0018] The term “PSM” refers to a group of amphipathic peptides with broad cytolytic activity and are an important virulence factor secreted by Staphylococci.
[0019] The term "type II TA-like element" refers to a binary system whose gene transcription mode, protein action mode and binding to its own promoter all meet the definition of a type II TA system, but whose toxin function does not conform to that of a type II TA element. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The effect of SA1833 / SA1832 on the survival of Staphylococcus aureus in ceftizoxime. (AD) SA1833 / SA1832 promotes the survival of Staphylococcus aureus in ceftizoxime. Each experiment was repeated three times, n=3, and the values were presented as mean±SD. The data were analyzed by Student's t-test. "ns" means not significant. In the figure, "*" means p<0.05, "**" means p<0.01, and "***" means p<0.001; "Δ" means the strain with the target gene knocked out (the "Δ" in the following figure has the same meaning).
[0021] Figure 2 SA1833 / SA1832 promotes the formation of cefuroxime retention in S. aureus. (A) Antibiotic time-kill curves of N315, ΔSA1833, ΔSA1832 and ΔSA1833-SA1832 strains show secondary killing characteristics; (B) The absence of SA1833, SA1832 and SA1833-SA1832 has no significant effect on the growth of S. aureus N315 strain.
[0022] Figure 3SA1833 / SA1832 deletion significantly inhibited the expression of lrgA. (A) Signal pathways involved in the regulation of SA1833-SA1832; (B) RT-qPCR detection of lrgA expression. The expression level of lrgA was significantly reduced in ΔSA1833, ΔSA1832 and ΔSA1833-SA1832; (C) SA1833 / SA1832 deletion downregulated the expression of lrgA, thereby inhibiting the growth of S. aureus in microaerobic medium with pyruvate as the main carbon source. Each experiment was repeated three times, n=3, and the values were presented as mean±SD. The data were analyzed by Student's t-test method. "ns" means not significant. In the figure, "*" means p<0.05, "**" means p<0.01, "***" means p<0.001, and "****" means p<0.0001.
[0023] Figure 4 The results of EMSA detection show that SA1833 can bind to the promoter of lrgA gene.
[0024] Figure 5 SA1833 / SA1832 regulates the persistence of S. aureus in an lrgA-dependent manner. (A) After the loss of lrgA, the survival ability of S. aureus in ceftizoxime was significantly weakened; (B) After lrgA complementation, the survival ability of SA1833-SA1832 deletion strains under ceftizoxime treatment was restored; (C) The ceftizoxime antibiotic time-kill curve of the lrgA deletion strain showed a secondary killing characteristic. Each experiment was repeated three times, n=3, and the values were presented as mean±SD. The data were analyzed by Student's t-test method. "ns" means not significant. In the figure, "*" means p<0.05, "**" means p<0.01, and "***" means p<0.001.
[0025] Figure 6SA1833 / SA1832 regulates the survival of S. aureus in macrophages and under dual stress of ceftizoxime in an lrgA-dependent manner. (A, B) The ability of S. aureus to infect macrophages is weakened after the loss of SA1833 / SA1832 / lrgA; (C, D) SA1833 / SA1832 regulates the survival of N315 strain in macrophage RAW264.7 in an lrgA-dependent manner; (E, F) SA1833 / SA1832 / lrgA loss weakens the survival of N315 strain under dual stress of macrophage intracellular stress environment and ceftizoxime. Each experiment was repeated three times, n=3, and the values are presented as mean±SD. The data were analyzed by Student's t-test method. "ns" means not significant. In the figure, "*" indicates p<0.05, "**" indicates p<0.01, "***" indicates p<0.001, and "****" indicates p<0.0001
[0026] Figure 7 This is the plasmid map of the pALC vector. DETAILED DESCRIPTION
[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0028] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. For example, the experimental methods not specifically indicated in the examples are all referred to: Pan Ting. Molecular mechanism of Staphylococcus aureus pyrophosphatase LcpB regulating cell wall synthesis and virulence [D]. University of Science and Technology of China, 2023. The materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial channels.
[0029] Example
[0030] Example 1 Construction of SA1833, SA1832, SA1833-SA1832 mutants and complemented strains
[0031] (1) Construction of SA1833 (NCBI gene accession number: SA1833), SA1832 (NCBI gene accession number: SA1832), SA1833-SA1832 and lrgA knockout vectors
[0032] By conventional methods, the genome of Staphylococcus aureus N315 (refer to the NARSA public sequence) was used as a template, and primers SA1833-up-F (SEQ ID NO.1) / SA1833-up-R (SEQ ID NO.2) and SA1833-down-F (SEQ ID NO.3) / SA1833-down-R (SEQ ID NO.4) were used to amplify the upstream and downstream homologous arms of SA1833 (about 750 bp each), respectively, and the upstream and downstream homologous arms were connected to the target gene by overlap PCR. Gel extraction was performed using StarPrep Gel Extraction KitStarPrep (manufactured by GenStar, D205-04, the method was in accordance with the kit instructions), and the spliced fragments were connected to the linearized plasmid pBTs (manufactured by Corey Biotech, KL-ZL-0864-01) using the homologous recombinase ClonExpress II (manufactured by Vazyme, C112-01) to form the pBTs-up-SA1833-down recombinant vector, i.e., the SA1833 knockout vector.
[0033] The method for constructing the SA1832 knockout vector was the same as that for constructing the SA1833 knockout vector, except that the primers used were replaced with SA1832-up-F (SEQ ID NO.5) / SA1832-up-R (SEQ ID NO.6) and SA1832-down-F (SEQ ID NO.7) / SA1832-down-R (SEQ ID NO.8) to amplify the SA1832 homology arms;
[0034] The method for constructing the SA1833-SA1832 knockout vector was the same as the method for constructing the SA1833 knockout vector, except that the primers used were replaced with SA1833-SA1832-up-F (SEQ ID NO.9) / SA1833-SA1832-up-R (SEQ ID NO.10) and SA1833-SA1832-down-F (SEQ ID NO.11) / SA1833-SA1832-down-R (SEQ ID NO.12) to amplify the SA1833-SA1832 homology arms;
[0035] The method for constructing the lrgA knockout vector refers to the method for constructing the above-mentioned knockout vector, except that the primers used are replaced with lrgA-up-F (SEQ ID NO.13) / lrgA-up-R (SEQ ID NO.14) and lrgA-down-F (SEQ ID NO.15) / lrgA-down-R (SEQ ID NO.16) to amplify the lrgA homology arm, which is the same as the method for constructing the SA1833 knockout vector.
[0036] (2) Construction of SA1833, SA1832, SA1833-SA1832 and lrgA complementation vectors
[0037] The gene fragment p(SA1833)-SA1833 containing the SA1833 promoter was amplified by conventional methods using the genome of Staphylococcus aureus N315 as a template and primers SA1833-(com)-F (SEQ ID NO.17) / SA1833-(com)-R (SEQ ID NO.18). p(SA1833)-SA1833 and pALC vector (sequence map as shown in Figure 1) were cleaved by restriction endonucleases (Thermo Fisher Scientific, FastDigest EcoRI: FD0274, FastDigest PstI: FD0614). Figure 7 The pALC vector was double-digested with enzymes (shown in Figure 1). The StarPrep Gel Extraction Kit StarPrep was used for gel extraction (the method was in accordance with the kit instructions), and the linearized vector pALC was ligated with the restriction fragment p(SA1833)-SA1833 (SEQ ID NO. 37) using T4 ligase (manufactured by Thermo Fisher Scientific, EL0011) to form a pALC-p(SA1833)-SA1833 recombinant plasmid, i.e., a SA1833 complementing plasmid.
[0038] The method for constructing the SA1832 complementing plasmid is the same as the method for constructing the SA1833 complementing plasmid, except that the primers used are replaced with SA1832-(com)-F (SEQ ID NO.19) / SA1832-(com)-R (SEQ ID NO.20) and SA1833-pro-(com)-F (SEQ ID NO.21) / SA1833-pro-(com)-R (SEQ ID NO.22) to amplify the SA1832 gene fragment p(SA1833)-SA1832 (SEQID NO.38) containing the SA1833 promoter;
[0039] The method for constructing the SA1833-SA1832 complementing plasmid is the same as the method for constructing the SA1833 complementing plasmid, except that the primers used are replaced with SA1833-SA1832-(com)-F (SEQ ID NO.23) / SA1833-SA1832-(com)-R (SEQ ID NO.24) to amplify the gene fragment p(SA1833)-SA1833-SA1832 (SEQ ID NO.39) containing the SA1833-SA1832 promoter;
[0040] Among them, SA1832 and SA1833 share the same promoter (ie, p(SA1833)), and SA1833-SA1832 are co-transcribed genes. Therefore, when preparing the SA1832 complementing plasmid, primers must be used to additionally amplify the promoter p(SA1833).
[0041] The method for constructing the lrgA complementing plasmid is the same as the method for constructing the SA1833 complementing plasmid, except that the primers are replaced with lrgA-(com)-F (SEQ ID NO.25) / lrgA-(com)-R (SEQ ID NO.26) to amplify the gene fragment p(lrgA)-lrgA (SEQ ID NO.40) containing the lrgA promoter.
[0042] (3) Genetic transformation and screening of Staphylococcus aureus
[0043] The plasmid prepared in the above step was mixed with the pre-prepared Staphylococcus aureus competent cells and placed in an ice bath for 30 minutes to complete the transformation and screening of the cells.
[0044] Example 2: Disruption of SA1833 / SA1832 reduces the survival ability of Staphylococcus aureus in cefuroxime
[0045] In order to explore the molecular mechanism of SA1833 / SA1832 regulating the persistence formation of Staphylococcus aureus under ceftizoxime treatment, the present invention used MRSA strain N315 (obtained from NARSA, NRS70) as the background strain, constructed SA1833, SA1832 and SA1833-SA1832 knockout strains by homologous recombination as described in Example 1, and detected their survival ability under ceftizoxime antibiotic treatment.
[0046] The SA1833 / SA1832 knockout strain prepared in Example 1 was streaked on TSB solid medium (manufactured by BD-Difco, 228200), inverted and cultured overnight at 37°C, and bacteria from 6 monoclonal colonies were picked and inoculated into TSB liquid medium (manufactured by BD-Difco, 214886), and cultured overnight at 37°C with shaking. To determine the growth status of the strain, OD 600 The bacteria from three clones with similar OD values were transferred into 5 mL of TSB liquid culture medium, and the concentration of the bacterial solution was adjusted to OD 600The concentration of 0.05 was used, and the culture was shaken at 37°C and 220rpm for 3 hours, and the bacterial solution in the early logarithmic phase (OD value between 0.5-0.8) was collected. The collected bacterial solution was centrifuged at 12000g and 4°C for 2 minutes, the supernatant was removed, and the bacteria were collected. The collected bacteria were washed 3 times with TSB liquid medium and resuspended, and the three groups of bacterial solutions were adjusted to the same concentration using TSB liquid medium. Take 100μL of bacterial solution and add it to a 96-well plate, then add 100μL of sublethal concentration (40μg / mL) of antibiotics to mix the bacterial solution, and place it in a 37°C bacterial incubator for static culture for 24 hours. After the static period, the bacterial solution was aspirated into an EP tube, centrifuged at 5000g and 4°C for 5 minutes, the supernatant was removed and the bacteria were collected. After washing the cells with PBS for 2-3 times, take an equal volume of PBS to resuspend the cells, dilute them in a gradient, and spread them on LB plates (1L of culture medium requires 10g Tryptone, 10g NaCl, 5g Yeast extract, 15g Agar). Incubate them upside down overnight at 37°C, count and calculate their survival rate. The calculation formula is as follows:
[0047] Survival rate = CFU number of bacteria under antibiotic treatment / CFU number without antibiotic treatment × 100%.
[0048] The results of the antibiotic treatment survival experiment of Staphylococcus aureus showed that the survival ability of Staphylococcus aureus under sublethal concentration (40 μg / mL) of cefuroxime was significantly reduced after the loss of SA1833 / SA1832 ( Figure 1 A), and after complementation of the corresponding gene in the SA1833 / SA1832 mutant, the survival ability of Staphylococcus aureus under the treatment of cefotaxime antibiotics can be restored ( Figure 1 B, D). The above results indicate that SA1833 / SA1832 is involved in regulating the survival of Staphylococcus aureus under sublethal concentrations of cefuroxime antibiotic treatment.
[0049] Example 3 SA1833 / SA1832 promotes the persistence of Staphylococcus aureus under cefuroxime treatment
[0050] To further verify that SA1833 / SA1832 is involved in regulating the persistence of Staphylococcus aureus to ceftizoxime antibiotics, this example detected the sensitivity of Staphylococcus aureus to ceftizoxime after knocking out SA1833 / SA1832, the antibiotic time-kill curve of the knockout strain, and the growth curve under aerobic conditions.
[0051] The SA1833 / SA1832 knockout strain prepared in Example 1 was streaked on TSB solid medium and incubated overnight at 37°C. Then, 10 bacteria from monoclonal colonies were picked and resuspended in MH2 liquid medium (manufactured by BD-Difco, 212322). The OD was adjusted to 600 After the concentration was reduced to 0.2, it was diluted 100 times and 75 μL of the bacterial solution was inoculated into a 96-well plate. To determine the maximum concentration of antibiotics required, MH2 medium was prepared with different concentrations of antibiotics (0.125 μg / mL-4 mg / mL), 75 μL of antibiotics of each concentration were taken and mixed with an equal volume of bacterial solution, and then observed and counted after shaking culture at 37°C for 24-48 hours to obtain the minimum antibiotic concentration (MIC) that inhibited bacterial growth.
[0052] Table 1 Antibiotic sensitivity test of gene knockout strains
[0053]
[0054] △: strain with knockout of target gene
[0055] The results of ceftizoxime sensitivity test showed that the MIC of N315 was 2 mg / mL, and the MIC of ΔSA1833, ΔSA1832 and ΔSA1833ΔSA1832 was 2 mg / mL (Table 1). The MIC value of the knockout strain was unchanged compared with the wild-type strain, indicating that SA1833 / SA1832 was not involved in regulating the resistance of Staphylococcus aureus to ceftizoxime.
[0056] The SA1833 / SA1832 knockout strain prepared in Example 1 was streaked on TSB solid medium and incubated upside down overnight at 37°C. Six monoclonal colonies of bacteria were picked and inoculated into TSB liquid medium and incubated overnight at 37°C with shaking. To determine the bacterial growth status, three OD 600 The bacteria of the cloned colonies with similar values were transferred to 10 mL TSB liquid medium and cultured at 37°C and 220 rpm until the early logarithmic phase (OD value 0.5-0.8). The bacteria were collected after centrifugation at 4°C and 5000 g for 15 min, and the cells were resuspended in TSB liquid medium and the cell concentration was adjusted to OD 600 2. Sublethal concentration (40 μg / mL) of ceftriaxone was added to the bacterial culture medium, and cultured at 37°C and 200 rpm. Samples were taken every 2 hours for a total of 5 times. The sampled cells were then centrifuged at 4°C and 8000g for 3 minutes to collect the bacteria, and washed 3 times with PBS. The bacteria were resuspended with an equal amount of PBS, diluted and plated, and placed in a 37°C incubator for overnight culture. The number of bacterial colonies was calculated, and the killing curve was drawn using Prism software (Graphpad).
[0057] The SA1833 / SA1832 knockout strain prepared in Example 1 was streaked on TSB solid medium and inverted overnight at 37°C. Six monoclonal colonies of bacteria were selected and inoculated into TSB liquid medium, respectively, and incubated overnight at 37°C with shaking. To determine the growth status of the strain, OD 600 For bacteria from three cloned communities with similar OD values, adjust the bacterial solution concentration to 600 0.05, and add the adjusted bacterial solution to a 96-well plate, add 150 μL to each well, and shake culture at 37°C for 12 hours. If the growth curve under a microaerobic environment is determined, the bacteria of three clones with similar growth states are transferred to anaerobic bottles containing 10 mL CDM medium (pyruvic acid as the main carbon source, for specific configuration, refer to: Hussain M, Hastings JG, White PJ. A chemically defined medium for slime production by coagulase-negative staphylococci. J Med Microbiol. 1991 Mar; 34 (3): 143-7.), and the initial concentration of the bacterial solution is adjusted to OD 600 The OD of the bacterial solution was measured by an enzyme-labeled instrument. 600 Samples were taken at 2-hour intervals until the bacteria reached a plateau (26 hours in this example), and a growth curve was drawn using Prism software (GraphPad). Figure 3 C).
[0058] The results of the antibiotic time-kill curve test showed that the SA1833 / SA1832 mutant strain showed secondary killing characteristics under the treatment of sublethal concentrations of antibiotics (referring to the rapid killing effect in a short period of time and the slow and continuous killing effect over a long period of time, which shows the game result of the death rate and growth rate of bacteria killed by antibiotics under the treatment of sublethal concentrations of antibiotics.) Figure 2 A), indicating that this gene is not involved in regulating the tolerance of Staphylococcus aureus to ceftizoxime. The growth curve results showed that SA1833 / SA1832 had no effect on the growth ability of Staphylococcus aureus under aerobic conditions and glucose as the main carbon source, excluding the possibility that knocking out SA1833 / SA1832 affects its growth ability and thus inhibits its survival under ceftizoxime treatment ( Figure 2 B). Figure 2B excluded the effect of knocking out SA1833 / SA1832 at sublethal concentrations on bacterial growth ability, thereby proving that SA1833 / SA1832 is involved in regulating the persistence of Staphylococcus aureus to cefuroxime, and proving that knocking out the gene achieves the killing effect of Staphylococcus aureus by reducing the bacterial persistence mechanism.
[0059] Example 4. SA1833 / SA1832 positively regulates the expression of lrgA
[0060] The present invention utilizes RNA-seq method to explore downstream target genes regulated by SA1833 / SA1832.
[0061] First, the SA1833 / SA1832 knockout strain prepared in Example 1 was streaked on TSB solid medium and inverted for overnight culture at 37°C. A single clone was picked and inoculated into TSB liquid medium and cultured overnight at 37°C for activation. The activated bacterial solution was transferred into fresh TSB liquid medium and the initial inoculation concentration was adjusted to OD 600 The cells were placed in a shaker at 37°C and cultured until the early logarithmic phase. The cells were centrifuged at 4°C and 12,000 g to collect 2OD 600of bacterial liquid. Add 1 mL of RNA isoPlus (Takara, 9108) to the bacterial precipitate collected by centrifugation, resuspend the bacteria, and transfer them to a crushing tube containing 0.6 g of zirconium oxide-silica beads. Since Staphylococcus aureus is a Gram-positive bacterium with a thick cell wall, an oscillating crusher (fastprep-24cell) was used to crush the cells at high speed. The cells were crushed twice, with an interval of 5 minutes each time, and the samples were placed on ice during this time. Crushing parameters: speed 6 m / s, time 40 s. Add 300 μL of chloroform to the cells, shake vigorously to mix, and centrifuge at 4°C and 12000g for 30 minutes. Add 500 μL of isopropanol to the RNase Free EP tube prepared in advance, aspirate the upper aqueous phase, add it to the EP tube containing isopropanol, invert to mix, and freeze at -80°C overnight to precipitate RNA. Take out the sample and place it on ice until it melts, then centrifuge it at 4°C and 12000g for 30 minutes, remove the liquid, and obtain RNA precipitation. Add 1ml of 75% ethanol to the centrifuge tube, centrifuge it at 4°C and 12000g for 10 minutes, remove the supernatant, and repeat this operation once. Then quickly centrifuge the EP tube at 4°C and 12000g for 30s, remove the residual liquid, and place it on ice until the precipitate becomes transparent, and add RNaseFree water (about 60μL) to dissolve the RNA. Use PrimeScript RT reagent Kit (Takara, RR037Q) for mRNA reverse transcription. Please refer to the kit manual for detailed steps. Afterwards, real-time quantitative fluorescence PCR detection was performed, and the sequences of the internal reference primers used are shown in SEQ ID NO.27 and 28.
[0062] The present invention uses RNA-seq method to explore the downstream target genes regulated by SA1833 / SA1832. The results show that after the destruction of SA1833-SA1832, the expression levels of genes related to metabolism, pathogenicity and external environmental signal processing in Staphylococcus aureus changed significantly ( Figure 3A), and changes in bacterial metabolic pathways are closely related to retention formation. Among them, it has been reported that lrgA can participate in the regulation of pyruvate transport in Staphylococcus aureus under anaerobic conditions (The Staphylococcus aureus CidA and LrgA Proteins Are Functional Holins Involved in the Transport of By-Products of Carbohydrate Metabolism. mBio. 2021Feb 22; 13(1): e0282721.), and is reported to be involved in the regulation of bacterial oxidative stress tolerance (Identification of the Streptococcus mutans LytST two-componentregulon reveals its contribution to oxidative stress tolerance. BMC Microbiol. 2012; 12: 187. Published 2012Sep 1.), and the persisting bacteria are a subpopulation of tolerant bacteria, and the mechanism of bacterial tolerance may also affect the formation of bacterial persistence. Therefore, in the embodiment of the present invention, the metabolism-related gene lrgA was selected as the downstream target gene regulated by SA1833 / SA1832 for subsequent analysis. RT-qPCR results showed that disruption of SA1833 / SA1832 significantly reduced the expression of lrgA ( Figure 3 B). It is known that lrgA can mediate the transport of pyruvate, a byproduct of carbon metabolism in bacteria, under microaerobic conditions. In order to further verify the regulation of SA1833 / SA1832 on lrgA, the present invention also detected the growth curve of Staphylococcus aureus under microaerobic conditions with pyruvate as the main carbon source. The growth curve results under microaerobic conditions showed that the growth of Staphylococcus aureus under microaerobic conditions with pyruvate as the main carbon source was significantly inhibited after the loss of SA1833 / SA1832 ( Figure 3 C). The above results indicate that SA1833 / SA1832 may regulate the retention of ceftizoxime by positively regulating the expression of lrgA, but whether this regulation is direct or indirect remains to be further verified.
[0063] Example 5. SA1833 / SA1832 can directly regulate the expression of lrgA
[0064] The present invention uses the electrophoretic mobility shift assay (EMSA) method to detect the regulation mode of SA1833 on lrgA.
[0065] Select the region containing the target gene promoter (100-200 bp) to design primers (SEQ ID NO. 29, 30), and label the phosphate backbone at the 5' end of the downstream primer with a 6-FAM fluorescent group. Use in a light-proof environment MaxDNA Polymerase (TaKaRa, R045A) was used to amplify the DNA probe fragment (SEQ ID NO. 41) using the N315 genome as a template, and the fluorescent probe was recovered by running the gel by electrophoresis (100 V, light-shielded 20 min). A 5% non-denaturing polyacrylamide gel (PAGE) was prepared and allowed to stand at 4°C for use.
[0066] To each reaction tube, 4 μL of EMSA binding reaction buffer (100 mM HEPES (pH 7.6), 5 mM EDTA, 50 mM (NH4)2SO4, 5 mM DTT, 1% Tween-20 and 150 mM KCl), 1 ng of DNA prepared by the above-mentioned process and proteins of gradient concentrations (0, 0.38, 0.77, 1.53, 3.07 fmol) were added. In the reaction tube with the highest protein concentration (3.07 fmol), the specific competitive probe (Unlabeled P lrgA ) (i.e., the above DNA probe without fluorescent label) or non-specific competitive probe (hu) (SEQ ID NO.42, whose probe primer sequences are shown in SEQ ID NO.31 and 32) was used as control, and the system was supplemented to 20 μL with PBS and incubated at 25°C for 20 min.
[0067] Take out the 5% PAGE gel, load the gel plate into the electrophoresis tank, add pre-cooled 1×TBE, and perform pre-electrophoresis at 4°C and 100V for 15min. After the above incubation is completed, add 5μL 5×Gel-shift loading buffer (0.25×TBF, 34% Glycerol, + / -0.2 (W / V) bromophenol blue) to each reaction tube, mix well and inject into the well for loading, and perform constant voltage electrophoresis at 90V for 1 hour at 4°C in a dark environment. After the electrophoresis is completed, the gel block is scanned and observed using a near-infrared fluorescence scanning imager.
[0068] The results showed that SA1833 could directly bind to the promoter of lrgA ( Figure 4 ), indicating that SA1833 can directly regulate the expression of lrgA and thus regulate the cefuroxime retention formation in Staphylococcus aureus.
[0069] Example 6. SA1833 / SA1832 regulates the formation of cefuroxime retention in Staphylococcus aureus via an lrgA-dependent pathway
[0070] In order to further confirm that SA1833 / SA1832 promotes the formation of cefuroxime retention in Staphylococcus aureus by regulating the expression of lrgA, the present invention constructed an lrgA knockout mutant and an lrgA-SA1833-SA1832 knockout mutant using the clinically derived N315 as the background strain.
[0071] First, the above mutant strains were constructed by referring to conventional methods using the knockout vectors prepared in Example 1. Then, the same methods as in Examples 2 and 3 were used to detect and analyze the survival ability and secondary killing curve of the lrgA mutant strain and the lrgA-SA1833-SA1832 mutant strain in sublethal concentrations of ceftriaxone.
[0072] The results of the survival test in sublethal concentrations of ceftizoxime showed that the survival ability of Staphylococcus aureus in ceftizoxime was significantly weakened after the loss of lrgA; the survival ability of ΔlrgA-SA1833-SA1832 was also significantly reduced compared with ΔSA1833-SA1832; while the survival ability of ΔlrgA was not significantly changed compared with ΔlrgA-SA1833-SA1832 ( Figure 5 A). Complementation of lrgA in the SA1833-SA1832 mutant strain restored the ability of Staphylococcus aureus to survive cefuroxime treatment ( Figure 5 B). In addition, the ceftizoxime sensitivity test results of the lrgA mutant strain showed that the MIC of ΔlrgA was 2 mg / mL, which was consistent with the wild type (Table 1). The ceftizoxime time-killing curve results of the lrgA mutant strain showed a secondary killing characteristic ( Figure 5 C), excluding the interference caused by tolerance. The above results indicate that SA1833 / SA1832 promotes the formation of persistence of Staphylococcus aureus under cefuroxime treatment by upregulating the transcription level of lrgA.
[0073] Example 7. SA1833 / SA1832 can promote the survival of Staphylococcus aureus in macrophages and under the dual stress of cefuroxime antibiotics, and this process depends on lrgA.
[0074] To further verify the result that the SA1833 / SA1832 mutant had a weakened ability to retain ceftizoxime, the ability of Staphylococcus aureus to infect mouse macrophages RAW264.7 (Wuhan Pronosai Life Science Technology Co., Ltd., CL-0190), its ability to survive in macrophages, and its ability to survive under the dual pressure of the intracellular environment and ceftizoxime antibiotic were tested.
[0075] 5×10 5RAW264.7 cells were inoculated into a 10 cm culture dish containing 12 mL of DMEM medium (gibco, C11995500BT) at a concentration of 10 / mL and cultured at 37°C and 5% CO2. When the cells were undifferentiated and the cell density reached 80%-90%, most of the culture medium was removed and the remaining culture medium was used to blow the bottom of the dish to resuspend the cells. Fresh DMEM medium was added to dilute the cells and counted on a hemocytometer to adjust the cell concentration to 3×10 6 / mL; Take 1mL of cell suspension, add it to a 12-well cell culture plate, and culture it in an incubator set to 5% CO2 and 37°C for 1 hour to promote cell adhesion. Streak the SA1833 / SA1832 knockout strain prepared in the above example on a TSB solid culture medium plate, pick a single clone, inoculate it in TSB liquid culture medium, activate it for one generation, transfer it to fresh TSB liquid culture medium, and culture it at 37°C with shaking until the early logarithmic phase. Centrifuge at 4°C and 12000g for 2 minutes, remove the supernatant and collect the bacteria, wash three times with PBS, resuspend the bacteria in DMEM culture medium, and adjust the bacterial concentration OD 600 0.3. Take 1mL of bacterial solution and add it to each well of the cell culture plate, infect RAW264.7 cells at an MOI of 50, and infect in a 37℃, 5% CO2 incubator for 1 hour. After the infection is completed, remove the culture medium, add 500μL of 100μg / mL gentamicin, and let it stand in a 37℃ incubator for 2 hours to kill extracellular bacteria. After the end, wash with PBS three times, resuspend the bacteria with PBS, and divide it into 2 parts for later use.
[0076] Centrifuge at 4°C and 1000g for 5 min, remove the supernatant and add 1 mL of cell lysis buffer (10 mM EDTA, 0.25% Triton-X 100 in PBS) to one of the cells, blow and mix to promote the lysis of infected RAW264.7 cells, dilute with PBS and apply to the plate. Invert and culture overnight at 37°C, calculate the number of CFU as the initial clone number; add an equal volume of DMEM medium to another cell and resuspend the cells. After spreading the cells in a 24-well cell culture plate, culture in a 5% CO2, 37°C incubator for 24 hours to detect the survival ability of bacteria in RAW264.7 cells. At the same time, in order to detect the ability of bacteria to retain antibiotics in cells, sublethal concentrations of antibiotics were added to the 24-well plate and placed in a 37°C incubator for 24 hours. After 24 hours of antibiotic treatment, the supernatant was removed and 1 mL of cell lysis buffer was added to each well to promote cell lysis. After PBS dilution and coating, the plates were inverted and cultured overnight at 37°C. The CFU number of bacteria after intracellular treatment was calculated, and the bacterial intracellular survival rate and intracellular retention ability were further calculated.
[0077] The results of infection experiments showed that after the loss of SA1833 / SA1832, the ability of Staphylococcus aureus to infect macrophages was weakened ( Figure 6 A), and this process depends on the expression of lrgA. After knocking out lrgA, the ability of Staphylococcus aureus to infect macrophages was significantly weakened ( Figure 6 B). Subsequently, the survival ability of Staphylococcus aureus in macrophages was tested, and the results showed that the survival ability of ΔSA1833 / SA1832 in macrophages was significantly weakened regardless of the presence or absence of ceftizoxime treatment ( Figure 6 C, D), and SA1833 / SA1832 regulates the formation of ceftizoxime retention in an lrgA-dependent manner ( Figure 6 E, F). The above results indicate that SA1833 / SA1832 can affect the retention of ceftizoxime by Staphylococcus aureus by regulating the expression of lrgA, thereby helping Staphylococcus aureus adapt to the intracellular stress of macrophages and achieve immune escape; in addition, it can also promote the survival of Staphylococcus aureus during ceftizoxime treatment, leading to the formation of clinical recurrent chronic infection of Staphylococcus aureus. Therefore, SA1833 / SA1832 can be used as a target in the preparation of drugs for the treatment of recurrent infection of methicillin-resistant Staphylococcus aureus.
[0078] In summary, the upregulation of lrgA expression level can promote the formation of Staphylococcus aureus retention, thereby promoting the survival of Staphylococcus aureus under oxidative stress and ceftizoxime antibiotic stimulation, indicating that SA1833 / SA1832 has the potential to become a target for treating recurrent infections of Staphylococcus aureus. The present invention uses the clinically derived methicillin-resistant strain N315 as a research object. The research results show that the destruction of SA1833 / SA1832 weakens the survival ability of Staphylococcus aureus in sublethal concentrations of ceftizoxime, and the ceftizoxime sensitivity of Staphylococcus aureus does not change after the loss of SA1833 / SA1832. The antibiotic time-kill curve of Staphylococcus aureus shows a secondary killing characteristic, indicating that SA1833 / SA1832 promotes the formation of ceftizoxime retention of Staphylococcus aureus. RNA-seq technology was used to preliminarily target the downstream target genes regulated by SA1833 / SA1832. This patent selected lrgA, a gene with significantly changed expression levels, for follow-up research, and RT-qPCR was used for preliminary verification. The results showed that SA1833 / SA1832 positively regulated the expression of lrgA; the microaerobic growth curve of Staphylococcus aureus was further verified. The results showed that after the loss of SA1833 / SA1832, the growth of Staphylococcus aureus under microaerobic conditions and pyruvate as the main carbon source slowed down significantly, which was consistent with the RT-qPCR results. The EMSA results showed that SA1833 can directly bind to the promoter of lrgA to regulate its expression. The results of the survival ability test of ΔlrgA in sublethal concentrations of ceftizoxime, the ceftizoxime antibiotic sensitivity test, and the time-kill curve test further confirmed that SA1833 / SA1832 promoted the formation of ceftizoxime retention in Staphylococcus aureus by upregulating the transcription level of lrgA. The results of Staphylococcus aureus infecting macrophages RAW264.7 showed that the ability of Staphylococcus aureus to infect macrophages was significantly weakened after knocking out SA1833, SA1832 and SA1833-SA1832. The results of the intracellular retention experiment showed that the survival ability of ΔSA1833 / SA1832 in macrophages was significantly reduced regardless of the presence or absence of ceftizoxime treatment. The above results suggest that SA1833 / SA1832 can promote Staphylococcus aureus to adapt to the intracellular stress environment of host cells and promote the formation of retained bacteria, thereby leading to the occurrence of chronic and recurrent infections. This patent reveals the molecular mechanism by which the Staphylococcus aureus toxin protein SA1833 / SA1832 regulates the formation of Staphylococcus aureus retention, thereby providing new targets for the development of drugs to treat recurrent infections caused by clinical MRSA strains, and providing more options for the treatment of Staphylococcus aureus.
[0079] Sequence Listing
[0080] SEQ ID NO.1: SA1833-up-F
[0081] ACGCGTCGACTCCTAGTGATATACGATAGCG
[0082] SEQ ID NO.2:SA1833-up-R
[0083] GTTGAACATTGGTTTATGCAGTCATAATTAAAATCCTCC
[0084] SEQ ID NO.3:SA1833-down-F
[0085] GCATAAACCAATGTTCAAC
[0086] SEQ ID NO.4:SA1833-down-R
[0087] CGGGGTACCGCCAACCATTACTATCCTT
[0088] SEQ ID NO.5:SA1832-up-F
[0089] ACGCGTCGACTTCAGAAACATACCCACTTA
[0090] SEQ ID NO.6:SA1832-up-R
[0091] CAAATATAAGTTAAGTACATTTTGGTTTATGCCTCCTTTAC
[0092] SEQ ID NO.7:SA1832-down-F
[0093] AAATGTACTTAACTTATATTTG
[0094] SEQ ID NO.8:SA1832-down-R
[0095] CGGGGTACCTTAACCAACTTACTCCATTCAG
[0096] SEQ ID NO.9:SA1833-SA1832-up-F
[0097] ACGCGTCGACTCCTAGTGATATACGATAGCG
[0098] SEQ ID NO.10:SA1833-SA1832-up-R
[0099] CTCTTTCGCTAATTCGTCCGACTGACTTCTCAATCAT
[0100] SEQ ID NO.11:SA1833-SA1832-down-F
[0101] GACGAATTAGCGAAAGAG
[0102] SEQ ID NO.12:SA1833-SA1832-down-R
[0103] CGGGGTACCTGCCAACCATTACTATCCT
[0104] SEQ ID NO.13:lrgA-up-F
[0105] GCGGAATTCGAGCTCGGTACCGTAAAAGAAACATTGGAAGCA
[0106] SEQ ID NO.14:lrgA-up-R
[0107] TGCCTCCTACGTTTGATT
[0108] SEQ ID NO.15:lrgA-down-F
[0109] AATCAAACGTAGGAGGCACCACTTAGCACTAAACAC
[0110] SEQ ID NO.16:lrgA-down-R
[0111] CTTGCATGCCTGCAGGTCGACATATCCCAGTTATAAACTGGA
[0112] SEQ ID NO.17:SA1833-(com)-F
[0113] ACGACGGCCAGTGAATTCATTCTGAAGGAGATATGTGCA
[0114] SEQ ID NO.18:SA1833-(com)-R
[0115] AAGCTTGCATGCCTGCAGGGTTTATGCCTCCTTTAC
[0116] SEQ ID NO.19:SA1832-(com)-F
[0117] ACCAATGTTCAACATTAATATTGA
[0118] SEQ ID NO.20:SA1832-(com)-R
[0119] AAGCTTGCATGCCTGCAGACATTTTCATTGCCTTGC
[0120] SEQ ID NO.21:SA1833-pro-(com)-F
[0121] ACGACGGCCAGTGAATTCATTCTGAAGGAGATATGTGCA
[0122] SEQ ID NO.22:SA1833-pro-(com)-R
[0123] TCAATATTAATGTTGAACATTGGTAATTAAAATCCTCCTTCGTTT
[0124] SEQ ID NO.23:SA1833-SA1832-(com)-F
[0125] ACGACGGCCAGTGAATTCATTCTGAAGGAGATATGTGCA
[0126] SEQ ID NO.24:SA1833-SA1832-(com)-R
[0127] AAGCTTGCATGCCTGCAGACATTTTCATTGCCTTGC
[0128] SEQ ID NO.25:lrgA-(com)-F
[0129] ACGACGGCCAGTGAATTCGAGCCATTGAATCGTTATGAA
[0130] SEQ ID NO.26:lrgA-(com)-R
[0131] AAGCTTGCATGCCTGCAGTTAATCATGAGCTTGTGCCTCC
[0132] SEQ ID NO.27:pta-F
[0133] AAAGCGCCAGGTGCTAAATTAC
[0134] SEQ ID NO.28:pta-R
[0135] CTGGACCAACTGCATCATATCC
[0136] SEQ ID NO.29:P lrgA -F
[0137] AAAGAAGTGCAACAATGGTTT
[0138] SEQ ID NO.30:P lrgA -R
[0139] TGCCTCCTACGTTTGATT
[0140] SEQ ID NO.31:P hu -F
[0141] AAAAAGAAGCTGGTTCAGCAGTAG
[0142] SEQ ID NO.32:P hu -R
[0143] TTTACGTGCAGCACGTTCAC
[0144] SEQ ID NO.33:down-SA1833-up sequence
[0145]
[0146] SEQ ID NO.34: down-SA1832-up gene fragment
[0147]
[0148] SEQ ID NO.35: down-SA1833-SA1832-up gene fragment
[0149]
[0150] SEQ ID NO.36: down-lrgA-up gene fragment
[0151]
[0152] SEQ ID NO.37: p(SA1833)-SA1833 gene fragment
[0153] GGTTTATGCCTCCTTTACTTCAAATTCAAATAATTCATTTACCTCAACTTGTAAAACTTCTGCCATTTTCTTAGCTAATTTAGGGCTTGGAATCTTTTTACCATTAATAATTTGGCTTAAATAAGAAATTCCAACACCTGTTTCACGTGATAAATCAGATAAATTAAAGCCTTTTAAGAACATGGCTTCTTTAAACTTTCTAGTATTCGCTAAAATAGTCATAATTAAAATCCTCCTTCGTTTTTGACTGACTTCTCAATCAATTTATAACTTTATTATACATAATCGTTTTTCTTTTGCAATAGTTTTTCGACTGACTTCTCAATCATTTTTTATTTTTTTGTACATAAACGTCCAAAAAAATGCTATTATTAACATAATTAGGAGGTTTGTAATGATTAGAAATAGATTGTCTGAACTACTGTCAGAAAGAGGACTAAAAATATCTCGTGTTGCAAAAGATGTAAAAATAGCAAGAAGTTCACTTACTTCAATGGCACAAAATGATTCTGAAATGATAAGATATGATGCTATAGATAAATTATGTAGTTATCTGCACATATCTCCTTCAGAAT
[0154] SEQ ID NO.38: p(SA1833)-SA1832 gene fragment
[0155] ACATTTTCATTGCCTTGCCTCCAATAACTTTTTGATATTGACTTGTTTAAAGTCGTTATTCTGGATATTCATATGAGCAGTAAGCTGTTCCATGAATTCATCTACATCAGACTTTTTGAATCTATACGTAGATCCGACCATATAATATTTCATGCCATTATTAATAAGTAATTCTTCAATAGTAGGCTTACTTAAATTCAGATAGTTAGACAACTCTTTGTAAGTCATAAAATATTTCTCTTTCGCTAATTCGTCCACACGTGCATTGATAGCCTGCTCAAGTAACTCACGTGCTTCATCTTCATCAATATTAATGTTGAACATTGGTAATTAAAATCCTCCTTCGTTTTTGACTGACTTCTCAATCAATTTATAACTTTATTATACATAATCGTTTTTCTTTTGCAATAGTTTTTCGACTGACTTCTCAATCATTTTTTATTTTTTTGTACATAAACGTCCAAAAAAATGCTATTATTAACATAATTAGGAGGTTTGTAATGATTAGAAATAGATTGTCTGAACTACTGTCAGAAAGAGGACTAAAAATATCTCGTGTTGCAAAAGATGTAAAAATAGCAAGAAGTTCACTTACTTCAATGGCACAAAATGATTCTGAAATGATAAGATATGATGCTATAGATAAATTATGTAGTTATCTGCACATATCTCCTTCA
[0156] SEQ ID NO.39: p(SA1833)-SA1833-SA1832 gene fragment
[0157] ACATTTTCATTGCCTTGCCTCCAATAACTTTTTGATATTGACTTGTTTAAAGTCGTTATTCTGGATATTCATATGAGCAGTAAGCTGTTCCATGAATTCATCTACATCAGACTTTTTGAATCTATACGTAGATCCGACCATATAATATTTCATGCCATTATTAATAAGTAATTCTTCAATAGTAGGCTTACTTAAATTCAGATAGTTAGACAACTCTTTGTAAGTCATAAAATATTTCTCTTTCGCTAATTCGTCCACACGTGCATTGATAGCCTGCTCAAGTAACTCACGTGCTTCATCTTCATCAATATTAATGTTGAACATTGGTTTATGCCTCCTTTACTTCAAATTCAAATAATTCATTTACCTCAACTTGTAAAACTTCTGCCATTTTCTTAGCTAATTTAGGGCTTGGAATCTTTTTACCATTAATAATTTGGCTTAAATAAGAAATTCCAACACCTGTTTCACGTGATAAATCAGATAAATTAAAGCCTTTTAAGAACATGGCTTCTTTAAACTTTCTAGTATTCGCTAAAATAGTCATAATTAAAATCCTCCTTCGTTTTTGACTGACTTCTCAATCAATTTATAACTTTATTATACATAATCGTTTTTCTTTTGCAATAGTTTTTCGACTGACTTCTCAATCATTTTTTATTTTTTTGTACATAAACGTCCAAAAAAATGCTATTATTAACATAATTAGGAGGTTTGTAATGATTAGAAATAGATTGTCTGAACTACTGTCAGAAAGAGGACTAAAAATATCTCGTGTTGCAAAAGATGTAAAAATAGCAAGAAGTTCACTTACTTCAATGGCACAAAATGATTCTGAAATGATAAGATATGATGCTATAGATAAATTATGTAGTTATCTGCACATATCTCCTTCAGAAT
[0158] SEQ ID NO.40: p(lrgA)-lrgA gene fragment
[0159] GAGCCATTGAATCGTTATGAAAAACGATTGAATCCCACTTATTTTATACGTATTCATCGTTCATATATTATTAACACGAAACACATTAAAGAAGTGCAACAATGGTTTAACTACACTTATATGGTAATATTGACAAATGGTGTCAAGATGCAAGTTGGACGTTCATTTATGAAAGATTTTAAAGCGTCGATAGGATTACTTTAACAGTAATCCTTTTTTTTATGCATTTTACCTATGATATTTTGTATTTCGGACTAAAAATCACGCAAATCGAAGTGAGCCATCTATACTTTAGTTAAATCAAACGTAGGAGGCAATGGTCGTGAAACAACAAAAAGACGCATCAAAACCAGCACACTTTTTTCACCAAGTCATTGTAATTGCTTTAGTACTCTTTGTATCGAAAATAATTGAATCATTTATGCCAATTCCTATGCCTGCATCAGTAATCGGTTTAGTATTATTATTTGTATTATTATGTACTGGTGCTGTTAAGTTAGGCGAAGTCGAAAAAGTAGGAACGACACTAACAAATAACATTGGCTTACTCTTCGTACCAGCCGGTATCTCAGTTGTTAACTCTTTAGGTGTCATTAGCCAAGCACCATTTTTAATCATTGGACTAATAATCGTCTCAACAATACTATTACTTATTTGTACTGGCTATGTCACACAAATTATTATGAAAGTTACTTCGAGATCTAAAGGTGACAAAGTCACAAAAAAGATCAAAATAGAGGAGGCACAAGCTCATGATTAAC
[0160] SEQ ID NO.41: lrgA promoter fragment
[0161] AAAGAAGTGCAACAATGGTTTAACTACACTTATATGGTAATATTGACAAATGGTGTCAAGATGCAAGTTGGACGTTTCATTTATGAAAGATTTTAAAGCGTCGATAGGATTACTTTAACAGTAATCCTTTTTTATGCATTTTACCTATGATATTTTGTATTTCGGACTAAAAATCACGCAAATCGAAGTGAGCCATCTATACTTTAGTTAAATCAAACGTAGGAGGCA
[0162] SEQ ID NO.42: hu promoter fragment
[0163] TTTACGTGCAGCACGTTCACGTACCTCAAAGTTACCGAAACCAATTAATTGTACTTTTTCACCTTTAGCAAGTGAGTTTTGGATTGATTCGAATACAGCATCTACTGCTGAACCAGCTTCTTTTTT
[0164] The above are only specific embodiments of the present disclosure and are not intended to limit the present disclosure. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present disclosure should be included in the protection scope of the present disclosure.
Claims
1. Use of the Staphylococcus aureus toxin protein-related genes SA1833 and / or SA1832 as targets in the preparation of drugs for treating drug-resistant Staphylococcus aureus infections, wherein the drug resistance is preferably methicillin resistance.
2. Use of gene knockout vectors or primers of Staphylococcus aureus toxin protein-related genes SA1833 and / or SA1832 in the preparation of drugs for treating drug-resistant Staphylococcus aureus infections; preferably, the primer sequence is as shown in any one of SEQ ID NO.1-12; preferably, the drug resistance is preferably methicillin resistance.
3. The use according to claim 1 or 2, wherein: The drug-resistant Staphylococcus aureus infection includes acute infection, chronic infection and recurrent infection.
4. A pharmaceutical composition, preferably for use in treating drug-resistant Staphylococcus aureus infection, characterized in that The pharmaceutical composition comprises a gene knockout vector or primers for the Staphylococcus aureus toxin protein-related genes SA1833 and / or SA1832, and an antibiotic; preferably, the primer sequence is shown in any one of SEQ ID NO.1-12.
5. The pharmaceutical composition according to claim 4, wherein The antibiotic is a β-lactam antibiotic, preferably cefuroxime.
6. A method for reducing the intracellular persistence of drug-resistant Staphylococcus aureus or reducing the survival rate of drug-resistant Staphylococcus aureus, characterized in that: The Staphylococcus aureus toxin protein-related genes SA1833 and / or SA1832 are knocked out.
7. The method according to claim 6, wherein: Knockdown of SA1833 and / or SA1832 downregulated the expression of the metabolism-related gene lrgA.
8. The method according to claim 6 or 7, wherein: The method also includes designing specific gene knockout primers, wherein the specific gene knockout primers are shown in any one of SEQ ID NOs. 1-12.
9. The method according to any one of claims 6 to 8, wherein: The primers are used to amplify the upstream and downstream homology arms of the target gene.
10. A gene knockout vector, characterized in that: It is a pBTs recombinant vector comprising a sequence shown in any one of SEQ ID NOs. 33-36.
Citation Information
Patent Citations
Application of nitrosation modification of transcriptional regulatory factors WalR and MgrA in treatment of staphylococcus aureus infection
CN114088946A
Methods and compositions to prevent microbial infection
US20190169623A1
